Rule 497(d)
FT 415
Bandwidth Select Portfolio, Series 3
e-Infrastructure Select Portfolio, Series 2
Genomics and Proteomics Select Portfolio Series
Global Technology Select Portfolio Series
Software Innovations 2000 Select Portfolio, Series 2
World Wide Wireless Select Portfolio, Series 2
Bandwidth Portfolio, Series 3
e-Infrastructure Portfolio, Series 2
Genomics and Proteomics Portfolio Series
Global Technology Portfolio Series
Software Innovations 2000 Portfolio, Series 3
World Wide Wireless Portfolio, Series 2
Supplement to the Prospectus dated March 3, 2000
Notwithstanding anything to the contrary in the Prospectus, Unit holders
who acquire Units of Genomics and Proteomics Select Portfolio Series or
Genomics and Proteomics Portfolio Series which, as a result of a reduction
in the aggregate underlying value of the Securities, are not subject to an
initial sales charge will be subject to the maximum remaining deferred sales
charge (initially $.225 per Unit for Genomics and Proteomics Select
Portfolio Series or $.35 per Unit for Genomics and Proteomics Portfolio
Series). In such case the maximum sales charge may exceed 3.25% of the Public
Offering Price for Genomics and Proteomics Select Portfolio Series or 4.5% of
the Public Offering Price per Unit for Genomics and Proteomics Portfolio
Series, but in no event will the maximum sales charge exceed 3.75% of the
Public Offering Price per Unit for Genomics and Proteomics Select Portfolio
Series or 5.50% of the Public Offering Price per Unit for Genomics and
Proteomics Portfolio Series.
March 14, 2000
